A follow-up study that evaluates the safety and clinical outcomes of subjects who have undergone hematopoietic stem cell transplantation with HSC835 (expanded umbilical cord blood hematopoietic stem cells)
|Effective start/end date||6/1/15 → 12/7/24|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.